Literature DB >> 12870121

Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation.

Matthew J Gonzales1, Eric Delwart, Soo-Yon Rhee, Rose Tsui, Andrew R Zolopa, Jonathan Taylor, Robert W Shafer.   

Abstract

We examined consecutive protease (PR) and reverse transcriptase (RT) sequences from human immunodeficiency virus (HIV) type 1-infected individuals, to distinguish changes resulting from sequence evolution due to possible superinfection. Between July 1997 and December 2001, >/=2 PR and RT samples from 718 persons were sequenced at Stanford University Hospital. Thirty-seven persons had highly divergent sequence pairs characterized by a nucleotide distance of >4.5% in PR or >3.0% in RT. In 16 of 37 sequence pairs, divergence resulted from the loss of mutations during a treatment interruption or from the gain of mutations with reinstitution of treatment. tat and/or gag sequencing of HIV-1 from cryopreserved plasma samples could be performed on 15 of the 21 divergent isolate pairs from persons without a treatment interruption. The sequences of these genes, unaffected by selective drug pressure, were monophyletic. Although HIV-1 PR and RT genes from treated persons may become highly divergent, these changes usually are the result of sequence evolution, rather than superinfection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870121      PMCID: PMC2547470          DOI: 10.1086/376534

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype.

Authors:  C Verhofstede; F V Wanzeele; B Van Der Gucht; N De Cabooter; J Plum
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

2.  Very young gay and bisexual men are at risk for HIV infection: the San Francisco Bay Area Young Men's Survey II.

Authors:  C R Waldo; W McFarland; M H Katz; D MacKellar; L A Valleroy
Journal:  J Acquir Immune Defic Syndr       Date:  2000-06-01       Impact factor: 3.731

3.  Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies.

Authors:  A Ibáñez; B Clotet; M A Martínez
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

4.  Gender differences in HIV-1 diversity at time of infection.

Authors:  E M Long; H L Martin; J K Kreiss; S M Rainwater; L Lavreys; D J Jackson; J Rakwar; K Mandaliya; J Overbaugh
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

5.  Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

Authors:  M J Gonzales; R N Machekano; R W Shafer
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

6.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

7.  Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.

Authors:  Rami Kantor; W Jeffrey Fessel; Andrew R Zolopa; Dennis Israelski; Nancy Shulman; Jose G Montoya; Michael Harbour; Jonathan M Schapiro; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

8.  High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

Authors:  R W Shafer; K Hertogs; A R Zolopa; A Warford; S Bloor; B J Betts; T C Merigan; R Harrigan; B A Larder
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

9.  Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy.

Authors:  M Nijhuis; C A Boucher; P Schipper; T Leitner; R Schuurman; J Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users.

Authors:  Artur Ramos; Dale J Hu; Lily Nguyen; Kim-Oanh Phan; Suphak Vanichseni; Nattawan Promadej; Kachit Choopanya; Margaret Callahan; Nancy L Young; Janet McNicholl; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more
  36 in total

1.  A gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission Pairs.

Authors:  Olivier Manigart; Debrah I Boeras; Etienne Karita; Paulina A Hawkins; Cheswa Vwalika; Nathan Makombe; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-03       Impact factor: 2.205

2.  Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing.

Authors:  Andrew D Redd; Aleisha Collinson-Streng; Craig Martens; Stacy Ricklefs; Caroline E Mullis; Jordyn Manucci; Aaron A R Tobian; Ethan J Selig; Oliver Laeyendecker; Nelson Sewankambo; Ronald H Gray; David Serwadda; Maria J Wawer; Stephen F Porcella; Thomas C Quinn
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

3.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 4.  Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design.

Authors:  Yang Gao; Wen Tian; Xiaoxu Han; Feng Gao
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

Review 5.  Polyvalent AIDS vaccines.

Authors:  Shan Lu; Jill M Grimes Serrano; Shixia Wang
Journal:  Curr HIV Res       Date:  2010-12       Impact factor: 1.581

6.  Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses.

Authors:  Colleen S Kraft; Debby Basu; Paulina A Hawkins; Peter T Hraber; Elwyn Chomba; Joseph Mulenga; William Kilembe; Naw H Khu; Cynthia A Derdeyn; Susan A Allen; Olivier Manigart; Eric Hunter
Journal:  Retrovirology       Date:  2012-03-20       Impact factor: 4.602

7.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

8.  Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.

Authors:  Rose Tsui; Belinda L Herring; Jason D Barbour; Robert M Grant; Peter Bacchetti; Alex Kral; Brian R Edlin; Eric L Delwart
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk?

Authors:  Mary S Campbell; Geoffrey S Gottlieb; Stephen E Hawes; David C Nickle; Kim G Wong; Wenjie Deng; Thomas M Lampinen; Nancy B Kiviat; James I Mullins
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women.

Authors:  Alan R Templeton; Melissa G Kramer; Joseph Jarvis; Jeanne Kowalski; Stephen Gange; Michael F Schneider; Qiujia Shao; Guang Wen Zhang; Mei-Fen Yeh; Hua-Ling Tsai; Hong Zhang; Richard B Markham
Journal:  Retrovirology       Date:  2009-06-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.